A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.

Tibotec Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 2007年10月4日最近更新: 2021年10月8日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects must meet all of the following criteria to be eligible for this trial:
•1. Aged between 18 and 70 years, extremes included;
•2. Documented chronic (diagnosis of hepatitis C > 6 months before the screening period) genotype 1a or 1b HCV infection (as assessed by line probe assay); treatment-naïve subjects or prior non-responding subjects/relapsers to previous treatment regimens (IFN/RBV or pegylated IFN/RBV), who did not discontinue anti-HVC therapy due to AEs; genotype 1 HCV patients with hemophilia or with stable methadone use may be enrolled; (subtyping in genotype 1a and 1b patients will also be done);
•3. ICF signed voluntarily before the first trial related activity;
•4. Able to comply with the protocol requirements and having good accessible veins;
•5. HCV plasma viral load of = 10,000 IU/mL at screening (as assessed by the Taqman assay);
•6. Bodyweight as defined by a Quetelet Index (Body Mass Index [BMI], weight in kg divided by the square of height in meters) between 18 and 32 kg/m², extremes included.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Subjects meeting one or more of the following criteria cannot be selected:
•1. Evidence of Child Pugh B or C liver disease or Metavir score 5 or 6 at screening; history or evidence of cirrhosis or decompensated liver disease defined as prior or current history of ascites, hepatic encephalopathy, bleeding esophageal or gastric varices. Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to hepatitis B, drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, non-alcoholic steatohepatitis, or primary biliary cirrhosis. Subjects with diagnosed or suspected hepatocellular carcinoma;
•2. Subjects receiving or having received polymerase inhibitor or protease inhibitor treatment for HCV during the 6 months before screening;
•3. Male subjects with female partners of childbearing potential not agreeing to use a reliable birth control method for 90 days after the last dosing of TMC435350 in the trial or as prescribed in the leaflet of the medication as administered in the SoC treatment period (when taking PegIFNa-2a in combination with RBV, all subjects must use effective birth control methods during treatment and for 7 months afterwards);
•4. Female, except if postmenopausal for over 2 years, or posthysterectomy, or post-tubal ligation (without reversal operation);
•5. History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in the Investigator’s opinion would compromise the subject’s safety and/or compliance with the trial procedures (period of non-drug/alcoholic misuse must at least be 1 month before the first administration of study medication).
•6. A positive urine drug test at screening. Urine will be tested to check the current use of amphetamines, cocaine, and opioids (with the exclusion of methadone).
•7. Subjects with at least one of the following laboratory abnormalities as defined by the Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Table (see
•Section 8.2, Addendum 2) at screening:
•- Bilirubin = 1.5x upper limit of laboratory normal range (ULN);
•- Platelet count < 80,000/mm3;
•- White blood cell (WBC) count < 2,000 cells/mm3;
•- Any other lab toxicity found to be clinically significant by the Investigator.
•8. Subjects coinfected with HIV-1 or HIV-2, or hepatitis A or B virus infection (confirmed by hepatitis A antibody immunoglobulin [IgM], or hepatitis B surface antigen [HBsAg]) at screening;
•9. Subjects with a pathologically prolonged QTc value (> 500 ms) at screening, or any active clinically significant disease (e.g., tuberculosis, cardiac dysfunction), or medical history or physical examination findings during screening that, in the Investigator’s opinion, would compromise the outcome of the trial;
•10. Subjects having uncontrolled/unstable diabetes, epilepsy, a manifest psychiatric disease;
•11. Non-stable methadone use or subjects having any other unstable disease;
•12. Subjects enrolled in another clinical trial within 90 days prior to screening.

研究者

发起方

Tibotec Pharmaceuticals Ltd

相似试验

进行中（未招募）

不适用

A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.

EUCTR2007-003289-16-NLTibotec Pharmaceuticals118

进行中（未招募）

不适用

EUCTR2007-003289-16-DETibotec Pharmaceuticals127

进行中（未招募）

1 期

EUCTR2007-003289-16-BETibotec Pharmaceuticals

进行中（未招募）

不适用

EUCTR2007-003289-16-GBTibotec Pharmaceuticals118

尚未招募

2 期

NL-OMON32015Janssen-Cilag16